Physician profile
Rose Natheer
NPI 1184030942
$1,117.81
in general payments reported to CMS, 2019-2025
17 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.05 · 2021: $136 · 2022: $340 · 2024: $262 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $490.56 | 2021-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $115.98 | 2025 | Cardioblate Gemini |
| Amgen INC. | $94.39 | 2019-2025 | Krystexxa, Repatha |
| Abbott Laboratories | $75.61 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $53.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.18 | 2022 | |
| Rgh Enterprises LLC | $47.98 | 2025 | |
| Astellas Pharma US INC | $35.35 | 2025 | Veozah |
| Solta Medical, A Division of Bausch Health US, LLC | $21.81 | 2024 | Clear+Brilliant |
| Paratek Pharmaceuticals, INC. | $20.53 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.34 | 2022 | |
| Lilly USA, LLC | $19.35 | 2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $17.39 | 2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $14.55 | 2022 | |
| Exact Sciences Corporation | $13.62 | 2024 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.12 | 2022 | |
| Glaxosmithkline, LLC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Natheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.